Comparison of intramuscular analgesic activity of butorphanol and morphine in patients with sickle cell disease.

[1]  B. Pack,et al.  Sickle cell disease. The painful episode. , 1983, The Nursing clinics of North America.

[2]  L Lasagna,et al.  Studies with different types of visual analog scales for measurement of pain , 1983, Clinical pharmacology and therapeutics.

[3]  M Rosen,et al.  The reliability of a linear analogue for evaluating pain , 1976, Anaesthesia.

[4]  B. Ameer,et al.  Drug therapy reviews: evaluation of butorphanol tartrate. , 1979, American journal of hospital pharmacy.

[5]  D. C. Mcleod,et al.  Comparative Effects and Analgesic Efficacy of the Agonist-Antagonist Opioids , 1983, Drug intelligence & clinical pharmacy.

[6]  E. Nikkila.  Letter: Serum high-density-lipoprotein and coronary heart-disease. , 1976, Lancet.

[7]  M. Brozovīc,et al.  PAIN RELIEF IN SICKLE CELL CRISES , 1986, The Lancet.

[8]  G. Kelen,et al.  The beta error and sample size determination in clinical trials in emergency medicine. , 1985, Annals of Emergency Medicine.

[9]  K. Baum,et al.  The Painful Crisis of Homozygous Sickle Cell Disease: A Study of Risk Factors , 1987 .

[10]  J. Lewis.  Evaluation of new analgesics. Butorphanol and nalbuphine. , 1980, JAMA.

[11]  P. Evans,et al.  Narcotic addiction in patients with chronic pain , 1981, Anaesthesia.

[12]  Vandam Ld.  Drug therapy: butorphanol. , 1980, The New England journal of medicine.

[13]  R. Powers.  Management protocol for sickle-cell disease patients with acute pain: impact on emergency department and narcotic use. , 1986, The American journal of emergency medicine.

[14]  J. Levine.  Pain and analgesia: the outlook for more rational treatment. , 1984, Annals of internal medicine.